Chromadex Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CDXC Nasdaq 8731 https://chromadex.com/default.aspx

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Chromadex Corp

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients - Jan 31st, 2023 1:32 pm
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis - Jan 17th, 2023 1:28 pm
Strong week for ChromaDex (NASDAQ:CDXC) shareholders doesn't alleviate pain of five-year loss - Jan 15th, 2023 1:52 pm
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB) - Jan 12th, 2023 1:34 pm
ChromaDex Named Brianna Gerber Chief Financial Officer - Jan 5th, 2023 1:33 pm
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers - Dec 27th, 2022 1:30 pm
Down 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a Turnaround - Dec 19th, 2022 2:35 pm
Here's Why ChromaDex (CDXC) is Poised for a Turnaround After Losing 7.5% in 4 Weeks - Dec 16th, 2022 2:35 pm
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States - Nov 11th, 2022 1:12 pm
Zacks.com featured highlights Oxford Industries, ChromaDex, UserTesting and TravelCenters of America - Nov 9th, 2022 10:02 am
ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates - Nov 2nd, 2022 9:35 pm
ChromaDex Corporation Reports Third Quarter 2022 Financial Results - Nov 2nd, 2022 8:02 pm
ChromaDex Corporation's (NASDAQ:CDXC) market cap rose US$16m last week; individual investors who hold 36% profited and so did insiders - Nov 2nd, 2022 3:40 pm
ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022 - Oct 26th, 2022 12:35 pm
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards - Oct 24th, 2022 12:32 pm
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment - Oct 11th, 2022 11:32 am
Trade Alert: Hoi Shuen Chau At ChromaDex Corporation (NASDAQ:CDXC), Has Just Spent US$1.2m Buying 14% More Shares - Oct 6th, 2022 12:53 pm
ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction - Oct 4th, 2022 10:32 am
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock - Oct 3rd, 2022 11:30 am
Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE) - Sep 19th, 2022 10:05 pm